Study summary

A new red-cell maturation drug freed about 4 in 10 transfusion-dependent people from transfusions

Elritercept phase 2 study · 87 people at the chosen dose, phase 2 · Presented 2024 (ASH, EHA); now in phase 3 with Takeda

What was tested

Elritercept (KER-050), an injection that blocks signals suppressing red-cell and platelet production, for transfusion-dependent lower-risk MDS.

What they found

• 41.3% of evaluable people were transfusion-free for at least 8 weeks in the first 24 weeks.
• Most responses were still ongoing at the data cutoff.

What it means

May work in people luspatercept helps less, and could also raise platelets.